CHICAGO (GenomeWeb) – A St. Jude Children’s Research Hospital-led team has identified a haplotype that appears to coincide with the risk of premature menopause in pediatric cancer survivors treated with gonadotoxic drugs.
Speaking at the American Society of Clinical Oncology here yesterday, Russell Brooke, a postdoctoral researcher in epidemiology and cancer control, presented preliminary findings from a search for variants associated with premature menopause in nearly 800 childhood cancer survivors from the St. Jude Lifetime Cohort.
Premature menopause has been documented in childhood cancer survivors, he explained. Consequently, there is interest in identifying those at highest risk of the long-term complication so that they can be offered appropriate counseling and fertility maintenance options, if available.
Some forms of treatment appear to be particularly prone to late-onset reproductive consequences. For example, Brooke was co-author on a study published in the Journal of Clinical Endocrinology and Metabolism in March by investigators at St. Jude Children’s Research Hospital and the Memorial Sloan Kettering Cancer Center that saw a related condition, premature ovarian insufficiency, in 10.9 percent of individuals from the St. Jude Lifetime Cohort Study in the two-dozen years after cancer diagnoses.
That study found enhanced levels of premature ovarian insufficiency in childhood